Latest news and press releases about Ensysce Biosciences, Inc. (ENSC): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose.
Price
| Price | $0.45 |
| Market Cap | $7M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -7.69 |
| EV / EBITDA | 0.16 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -316.63% |
| Return on Invested Capital | -320.89% |
| Return on Assets | -136.54% |
| Gross Margin | 100.00% |
| Operating Margin | -1087.47% |
| Net Margin | -1084.23% |
Related companies: AIM · CANF · KALA · KZIA · OGEN · QLGN · SNGX
Explore sector: Healthcare · Biotechnology
More sections of ENSC: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks